Should You Buy Regeneron Pharmaceuticals Inc (REGN) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
751.130
1 Day change
-2.61%
52 Week Range
821.110
Analysis Updated At
2026/01/26
Regeneron Pharmaceuticals Inc (REGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong growth prospects driven by Dupixent and Eylea HD, positive analyst sentiment with multiple price target upgrades, and solid financial performance in the latest quarter. While technical indicators are neutral, the long-term fundamentals and positive catalysts outweigh short-term volatility.
Technical Analysis
The MACD histogram is -5.317, below 0, and negatively contracting, indicating a bearish momentum. RSI is neutral at 47.475, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. Key support is at 725.411, and resistance is at 803.897. The stock is currently trading near support levels, which could present a buying opportunity.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
6
Buy
5
Positive Catalysts
Analysts have raised price targets significantly, with the highest target at $1,057, reflecting strong confidence in the company's growth prospects.
Hedge funds are increasing their positions, with a 167% rise in buying activity last quarter.
Regeneron recently gained approval for a higher-dose Eylea, which could boost revenue.
Financial performance in Q3 2025 showed growth in revenue (+0.90% YoY), net income (+8.91% YoY), and EPS (+18.02% YoY).
Neutral/Negative Catalysts
Insiders are selling, with a 327.40% increase in selling activity over the last month.
Gross margin dropped slightly (-0.79% YoY), indicating some cost pressures.
Technical indicators are neutral to bearish, with no clear upward momentum in the short term.
Financial Performance
In Q3 2025, Regeneron's revenue increased to $3.75 billion (+0.90% YoY), net income rose to $1.46 billion (+8.91% YoY), and EPS grew to $13.62 (+18.02% YoY). However, gross margin declined slightly to 86.11% (-0.79% YoY). Overall, the financials indicate strong profitability and growth.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts are highly bullish on REGN, with multiple upgrades and raised price targets. Evercore ISI raised the target to $875, Goldman Sachs to $914, BofA to $860, Citi to $900, and Canaccord to $1,057. Analysts highlight Dupixent and Eylea HD as key growth drivers, along with a strong pipeline and improving fundamentals.
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.5 USD with a low forecast of 637 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.5 USD with a low forecast of 637 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 771.250
Low
637
Averages
808.5
High
1057
Current: 771.250
Low
637
Averages
808.5
High
1057
Bernstein
Outperform
maintain
$911 -> $916
AI Analysis
2026-01-27
New
Reason
Bernstein
Price Target
$911 -> $916
AI Analysis
2026-01-27
New
maintain
Outperform
Reason
Bernstein raised the firm's price target on Regeneron (REGN) to $916 from $911 and keeps an Outperform rating on the shares ahead of quarterly results. For Eylea, Q4 results were already pre-announced, so the firm will be looking more toward management commentary on potential for further acceleration in HD launch, where it is bullish. For Dupixent, Bernstein is in-line on 4Q product sales and model a 2% beat on Sanofi (SNY) collaboration revenues.
Evercore ISI
Outperform
maintain
$750 -> $875
2026-01-22
Reason
Evercore ISI
Price Target
$750 -> $875
2026-01-22
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Regeneron to $875 from $750 and keeps an Outperform rating on the shares. Regeneron is "looking strong with a refreshed outlook" and recent price hikes, argues the analyst. The company's growth prospects are "particularly buoyed" by Dupixent and Eylea HD, which are positioned well to compete in the market, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REGN
